212 related articles for article (PubMed ID: 36282806)
1. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
[TBL] [Abstract][Full Text] [Related]
2. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
3. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
4. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
5. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
6. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
7. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.
Treitler PC; Bowden CF; Lloyd J; Enich M; Nyaku AN; Crystal S
J Subst Abuse Treat; 2022 Jan; 132():108514. PubMed ID: 34098210
[TBL] [Abstract][Full Text] [Related]
8. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
9. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
[TBL] [Abstract][Full Text] [Related]
10. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
11. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
12. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
[TBL] [Abstract][Full Text] [Related]
13. "Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment.
Suen LW; Steiger S; Shapiro B; Castellanos S; Joshi N; Lambdin BH; Knight KR
Int J Drug Policy; 2023 Nov; 121():104214. PubMed ID: 37778132
[TBL] [Abstract][Full Text] [Related]
14. "Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED.
Schoenfeld EM; Westafer LM; Beck SA; Potee BG; Vysetty S; Simon C; Tozloski JM; Girardin AL; Soares WE
Acad Emerg Med; 2022 Aug; 29(8):928-943. PubMed ID: 35426962
[TBL] [Abstract][Full Text] [Related]
15. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
[No Abstract] [Full Text] [Related]
16. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
17. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
Brothers S; Palayew A; Simon C; Coulter A; Strichartz K; Voyles N; Vincent L
Harm Reduct J; 2023 Mar; 20(1):31. PubMed ID: 36894968
[TBL] [Abstract][Full Text] [Related]
18. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
19. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
20. Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.
Button D; Cook R; King C; Khuyen TT; Kunkel L; Bart G; Thuy DT; Nguyen DB; Blazes CK; Giang LM; Korthuis PT
Int J Drug Policy; 2022 Feb; 100():103503. PubMed ID: 34768124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]